Clinical Trial Update: A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Anakinra to IVIG retreatment in Kawasaki disease patients who did not respond to initial IVIG therapy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kawasaki Disease

Drugs mentioned

• Anakinra (anakinra)
• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Kawasaki Disease | Phase 3 | Status: RECRUITING